CoChat

Toll-Like Receptor Expression in the Blood and Brain of Patients and a Mouse Model of Parkinson's Disease

Open access
Drouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., Cicchetti, F. · 2015 · International Journal of Neuropsychopharmacology

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Accumulating evidence supports a role for the immune system in the pathogenesis of Parkinson's disease. Importantly, recent preclinical studies are now suggesting a specific contribution of inflammation to the α-synuclein-induced pathology seen in this condition. METHODS: We used flow cytometry and western blots to detect toll-like receptor 2 and 4 expression in blood and brain samples of Parkinson's disease patients and mice overexpressing human α-synuclein. To further assess the effects of α-synuclein overexpression on the innate immune system, we performed a longitudinal study using Thy1.2-α-synuclein mice that expressed a bicistronic DNA construct (reporter genes luciferase and green fluorescent protein) under the transcriptional control of the murine toll-like receptor 2 promoter. RESULTS: Here, we report increases in toll-like receptors 2 and 4 expression in circulating monocytes and of toll-like receptor 4 in B cells and in the caudate/putamen of Parkinson's disease patients. Monthly bioluminescence imaging of Thy1.2-α-synuclein mice showed increasing toll-like receptor 2 expression from 10 months of age, although no change in toll-like receptor 2 and 4 expression was observed in the blood and brain of these mice at 12 months of age. Dexamethasone treatment starting at 5 months of age for 1 month significantly decreased the microglial response in the brain of these mice and promoted functional recovery as observed using a wheel-running activity test. CONCLUSION: Our results show that toll-like receptors 2 and 4 are modulated in the blood and brain of Parkinson's disease patients and that overexpression of α-synuclein leads to a progressive microglial response, the inhibition of which has a beneficial impact on some motor phenotypes of an animal model of α-synucleinopathy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyu103

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Toll-like receptor (TLR)2 and TLR4 expression in peripheral blood cells of Parkinson’s disease (PD) patients. (A) Quantification of mean fluorescence intensity (MFI) of TLR2 and TLR4 shows an increase of CD45+ leukocytes in PD patients (n=12) vs controls (CTL) (n=9). (B-E) Subpopulation analysis reveals an increase in TLR4 MFI in CD45+/CD19+ B cells and of both receptors in CD14+ monocytes. Gating strategy is shown for each cell type analyzed. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. *P<.05.
Figure 1. Toll-like receptor (TLR)2 and TLR4 expression in peripheral blood cells of Parkinson’s disease (PD) patients. (A) Quantification of mean fluorescence intensity (MFI) of TLR2 and TLR4 shows an increase of CD45+ leukocytes in PD patients (n=12) vs controls (CTL) (n=9). (B-E) Subpopulation analysis reveals an increase in TLR4 MFI in CD45+/CD19+ B cells and of both receptors in CD14+ monocytes. Gating strategy is shown for each cell type analyzed. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. *P<.05.CC BY-NC · PubMed Central
Figure 2. Toll-like receptor (TLR)2 and TLR4 expression in the brain of Parkinson’s disease (PD) patients. (A-B) Western blot quantification of TLR2, TLR4, and molecules involved in their downstream pathways (myeloid differentiation primary response gene (88) [MyD88], TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β [TRIS], nuclear factor κB [NF-κB]in the striatum of PD patients (n=7) compared to age- and gender-matched controls (CTL or C) (n=6). Data are expressed as a ratio over β-actin. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. *P<.05; **P<.01.
Figure 2. Toll-like receptor (TLR)2 and TLR4 expression in the brain of Parkinson’s disease (PD) patients. (A-B) Western blot quantification of TLR2, TLR4, and molecules involved in their downstream pathways (myeloid differentiation primary response gene (88) [MyD88], TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β [TRIS], nuclear factor κB [NF-κB]in the striatum of PD patients (n=7) compared to age- and gender-matched controls (CTL or C) (n=6). Data are expressed as a ratio over β-actin. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. *P<.05; **P<.01.CC BY-NC · PubMed Central
Figure 3. Toll-like receptor (TLR)2 and TLR4 expression in the brain of Thy1.2-α-synuclein (αSyn)× TLR2-GFP-fluc mice. Schematic diagram of the Thy1.2-αSyn (Rockenstein et al., 2002) and TLR2-GFP-fluc (Lalancette-Hebert et al., 2009) constructs that were used to generate the Thy1.2-αSyn×TLR2-GFP-fluc mice. (B) Immunofluorescent staining of human αSyn (hαSyn) showing none in a littermate nontransgenic for the hαSyn gene and strong expression in the transgenic mouse. Treatment with Proteinase K confirms the presence of αSyn in the substantia nigra of Thy1.2-αSyn×TLR2-GFP-fluc mice. (C) Western blot quantification of TLR2, TLR4, and molecules involved in their pathways (myeloid differentiation primary response gene (88) [MyD88], TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β [TRIS], Nuclear factor κB [NF-κB]-p65), as well as hαSyn and total αSyn, in the striatum of Thy1.2-αSyn×TLR2-GFP-fluc mice (n=9) compared to wild type×TLR2-GFP-fluc littermates (n=9) at 12 months of age. Western blot data are expressed as a ratio over β-actin. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. hαSyn-/-, TLR2-GFP-fluc mice; hαSyn-/-, Thy1.2-αSyn×TLR2-GFP-fluc mice; SNCA, synuclein, Alpha (Non A4 Component Of Amyloid Precursor); TRIS, TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β (TRIF). Scale bar=100 µm, inset=25 µm, lower row=50 µm.
Figure 3. Toll-like receptor (TLR)2 and TLR4 expression in the brain of Thy1.2-α-synuclein (αSyn)× TLR2-GFP-fluc mice. Schematic diagram of the Thy1.2-αSyn (Rockenstein et al., 2002) and TLR2-GFP-fluc (Lalancette-Hebert et al., 2009) constructs that were used to generate the Thy1.2-αSyn×TLR2-GFP-fluc mice. (B) Immunofluorescent staining of human αSyn (hαSyn) showing none in a littermate nontransgenic for the hαSyn gene and strong expression in the transgenic mouse. Treatment with Proteinase K confirms the presence of αSyn in the substantia nigra of Thy1.2-αSyn×TLR2-GFP-fluc mice. (C) Western blot quantification of TLR2, TLR4, and molecules involved in their pathways (myeloid differentiation primary response gene (88) [MyD88], TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β [TRIS], Nuclear factor κB [NF-κB]-p65), as well as hαSyn and total αSyn, in the striatum of Thy1.2-αSyn×TLR2-GFP-fluc mice (n=9) compared to wild type×TLR2-GFP-fluc littermates (n=9) at 12 months of age. Western blot data are expressed as a ratio over β-actin. All data are expressed as group means±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. hαSyn-/-, TLR2-GFP-fluc mice; hαSyn-/-, Thy1.2-αSyn×TLR2-GFP-fluc mice; SNCA, synuclein, Alpha (Non A4 Component Of Amyloid Precursor); TRIS, TIR-less splice variant of TIR-domain-containing adapter-inducing interferon-β (TRIF). Scale bar=100 µm, inset=25 µm, lower row=50 µm.CC BY-NC · PubMed Central
Figure 4. Toll-like receptor (TLR)2 and TLR4 expression in peripheral blood cells of Thy1.2-αSyn×TLR2-GFP-fluc mice. (A) Quantification of mean fluorescence intensity (MFI) of TLR2 and TLR4 shows no change in CD45+/CD19+ B cells or in CD115+/CD11b monocytes (n=8–9 mice per group). (B) Gating strategy is represented for each cell type assessed using flow cytometry. All data are expressed as group means ±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. hαS, human α-synuclein.
Figure 4. Toll-like receptor (TLR)2 and TLR4 expression in peripheral blood cells of Thy1.2-αSyn×TLR2-GFP-fluc mice. (A) Quantification of mean fluorescence intensity (MFI) of TLR2 and TLR4 shows no change in CD45+/CD19+ B cells or in CD115+/CD11b monocytes (n=8–9 mice per group). (B) Gating strategy is represented for each cell type assessed using flow cytometry. All data are expressed as group means ±SEM. Statistical analyses were performed using an unpaired Student’s t test with a Welch correction in case of unequal variance. hαS, human α-synuclein.CC BY-NC · PubMed Central
Figure 5. Microglial response in the Thy1.2-αSyn×TLR2-GFP-fluc mouse model and its impact on motor deficits. (A) Immunofluorescent staining of Iba1 (microglia) showing a strong microglial response in the striatum and substantia nigra (SN) of the Thy1.2-αSyn transgenic mouse as compared to non-transgenic littermates at 12 months, but not at 6 months. (B) Longitudinal measurements of the brain microglial response using bioluminescent imaging displayed a significant increase in the toll-like receptor (TLR)2 signal at 10 months onwards (n=3–21 per group). (C) The decrease in total distance traveled in a 12-hour nocturnal session of wheel activity was reversed with dexamethasone treatment (n=7–8 per group). Locomotor activity assessed in a 1-hour session using the open field test confirms hyperactivity in Thy1.2-αSyn × TLR2-GFP-fluc mice, as evidenced by an increase in total distance traveled, average speed, as well as central and peripheral movements. However, these motor features were not reversed by dexamethasone. All data are expressed as group means ± SEM. Statistical analyses were performed using a 2-way ANOVA. P<.05 compared with saline-treated TLR2-GFP-fluc mice; #P<.05 and ##P<.01 compared with dexamethasone-treated TLR2-GFP-fluc mice; φφφ = p < .001 compared with dexamethasone-treated Thy1.2-αSyn × TLR2-GFP-fluc mice. (D) Bioluminescent imaging corroborates a decrease in TLR2 signal in Thy1.2-αSyn×TLR2-GFP-fluc mice that received dexamethasone treatment (n=6 per group). Statistical analyses were performed using Mann-Whitney U test. *P<.05. hαS-/-, TLR2-GFP-fluc mice; hαS-/+, Thy1.2-αSyn x TLR2-GFP-fluc mice; Dex, dexamethasone; Sal, saline. Scale bar (A) = 100 µm.
Figure 5. Microglial response in the Thy1.2-αSyn×TLR2-GFP-fluc mouse model and its impact on motor deficits. (A) Immunofluorescent staining of Iba1 (microglia) showing a strong microglial response in the striatum and substantia nigra (SN) of the Thy1.2-αSyn transgenic mouse as compared to non-transgenic littermates at 12 months, but not at 6 months. (B) Longitudinal measurements of the brain microglial response using bioluminescent imaging displayed a significant increase in the toll-like receptor (TLR)2 signal at 10 months onwards (n=3–21 per group). (C) The decrease in total distance traveled in a 12-hour nocturnal session of wheel activity was reversed with dexamethasone treatment (n=7–8 per group). Locomotor activity assessed in a 1-hour session using the open field test confirms hyperactivity in Thy1.2-αSyn × TLR2-GFP-fluc mice, as evidenced by an increase in total distance traveled, average speed, as well as central and peripheral movements. However, these motor features were not reversed by dexamethasone. All data are expressed as group means ± SEM. Statistical analyses were performed using a 2-way ANOVA. P<.05 compared with saline-treated TLR2-GFP-fluc mice; #P<.05 and ##P<.01 compared with dexamethasone-treated TLR2-GFP-fluc mice; φφφ = p < .001 compared with dexamethasone-treated Thy1.2-αSyn × TLR2-GFP-fluc mice. (D) Bioluminescent imaging corroborates a decrease in TLR2 signal in Thy1.2-αSyn×TLR2-GFP-fluc mice that received dexamethasone treatment (n=6 per group). Statistical analyses were performed using Mann-Whitney U test. *P<.05. hαS-/-, TLR2-GFP-fluc mice; hαS-/+, Thy1.2-αSyn x TLR2-GFP-fluc mice; Dex, dexamethasone; Sal, saline. Scale bar (A) = 100 µm.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Research works printed but not linked: 1

  1. 2013, 4, 23

Cited by

Metadata

Authors
Drouin-Ouellet, J., St-Amour, I., Saint-Pierre, M., Lamontagne-Proulx, J., Kriz, J., Barker, R. A., & Cicchetti, F.
Affiliations
University of Cambridge (GB)
Corresponding author
Cicchetti, F.
Venue
International Journal of Neuropsychopharmacology
Published
2014-12-07
Volume
18
Issue
6
Pages
pyu103-pyu103
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2114037757
Cited by
153
References
63
Citations by year
2026: 4 · 2025: 13 · 2024: 19 · 2023: 11 · 2022: 21 · 2021: 19 · 2020: 17 · 2019: 12 · 2018: 19 · 2017: 7 · 2016: 6 · 2015: 5
FWCI
3.91
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Parkinson Society Canada
  • National Institute for Health and Care Research
  • Parkinson's UK
  • University of Cambridge
  • Imperial College London
  • Canadian Institutes of Health Research
  • Fonds de Recherche du Québec - Santé
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords
Parkinson's disease, TLR2, TLR4, alpha-synuclein, neuroinflammation, microglia, innate immunity, circulating monocytes, B cells, caudate-putamen, synucleinopathies, dexamethasone, motor recovery, bioluminescence imaging
MeSH terms
Aged, Aged, 80 and over, Animals, Antiparkinson Agents, B-Lymphocytes, Brain, Dexamethasone, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Monocytes, Parkinson Disease, Time Factors, Up-Regulation, Case-Control Studies, Microglia, Green Fluorescent Proteins, Toll-Like Receptors, Toll-Like Receptor 2, Toll-Like Receptor 4, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.